CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects.
BACS-SC, Brief Assessment of Cognition in Schizophrenia Symbol Coding
BMI, body mass index
BVMT-R, Brief Visuospatial Memory Test-Revised
CGI, Clinical Global Impression
CPT-IP, Continuous Performance Test-Identical Pairs
DUP, duration of untreated psychosis
FEP, first-episode psychosis
GAF, Global Assessment of Functioning
HC, healthy controls
HVLT-R, Hopkins Verbal Learning Test-Revised
LNS, Letter-Number Span
MSCEIT, Mayer–Salovey– Caruso Emotional Intelligence Test
NAB: MAZES, Neuropsychological Assessment Battery: Mazes
PANSS, the Positive and Negative Syndrome Scale
SNAP-25
SYT-1
Schizophrenia
Synapse pruning
TMT, Trail Making Test
WMS-III, Wechsler Memory Scale-3rd Edition
Journal
IBRO reports
ISSN: 2451-8301
Titre abrégé: IBRO Rep
Pays: England
ID NLM: 101691215
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
22
10
2019
accepted:
01
04
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and
Identifiants
pubmed: 32490278
doi: 10.1016/j.ibror.2020.04.001
pii: S2451-8301(20)30011-X
pmc: PMC7262376
doi:
Types de publication
Journal Article
Langues
eng
Pagination
136-142Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
Sophie Erhardt has received grant support from AstraZeneca and Jansen Pharmaceuticals as principal investigator and has been a speaker for Roche Pharmaceuticals, Astra Zeneca, Eli Lilly and Bristol Myers Squibb. Carl Sellgren is a co-founder of Outermost Therapeutics Inc. HZ has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KB has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. There are no commercial associations that might pose a conflict of interest in connection with the manuscript. No funding sources had any role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. None of the other authors declare any competing interests.
Références
Biol Psychiatry. 2015 Sep 15;78(6):361-73
pubmed: 25662103
J Psychiatry Neurosci. 2010 Mar;35(2):95-104
pubmed: 20184807
Arch Gen Psychiatry. 2005 Apr;62(4):379-86
pubmed: 15809405
Schizophr Bull. 2009 May;35(3):509-27
pubmed: 19155345
Mol Neurodegener. 2014 Nov 23;9:53
pubmed: 25418885
Biochem Biophys Res Commun. 2016 Apr 1;472(2):319-23
pubmed: 26926566
Neuron. 2002 May 16;34(4):599-611
pubmed: 12062043
Mol Psychiatry. 2004 Jun;9(6):609-20, 544
pubmed: 14708030
Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):555-563
pubmed: 29404686
Brain. 1999 Apr;122 ( Pt 4):593-624
pubmed: 10219775
Arch Gen Psychiatry. 1997 Jun;54(6):559-66
pubmed: 9193197
Alzheimers Res Ther. 2016 Oct 3;8(1):41
pubmed: 27716408
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13281-6
pubmed: 21788513
Lancet Psychiatry. 2018 Nov;5(11):885-894
pubmed: 30322824
Schizophr Res. 1999 Nov 9;40(1):23-9
pubmed: 10541003
Biol Psychiatry. 2000 Aug 1;48(3):184-96
pubmed: 10924661
CNS Spectr. 2017 Oct;22(5):415-426
pubmed: 28181901
Neurosci Lett. 2002 Jan 14;317(3):161-5
pubmed: 11755264
Neuron. 2004 Feb 19;41(4):599-610
pubmed: 14980208
Nat Neurosci. 2019 Mar;22(3):374-385
pubmed: 30718903
Curr Top Behav Neurosci. 2010;4:243-81
pubmed: 21312403
Biol Psychiatry. 2002 Jun 15;51(12):1008-11
pubmed: 12062886
Biol Psychiatry. 1998 Feb 15;43(4):239-43
pubmed: 9513732
Mol Cell Proteomics. 2014 Oct;13(10):2584-92
pubmed: 24973420
Neuroscience. 2013 Oct 22;251:90-107
pubmed: 22546337
Neuroscience. 2009 Jan 12;158(1):223-30
pubmed: 18514426
Cereb Cortex. 1998 Apr-May;8(3):261-8
pubmed: 9617921
Eur Neuropsychopharmacol. 2017 Jan;27(1):8-18
pubmed: 27919523
Br J Psychiatry. 1998 Feb;172:110-20
pubmed: 9519062
Biol Psychiatry. 2003 Jun 15;53(12):1132-7
pubmed: 12814864
Int J Neuropsychopharmacol. 2012 Jun;15(5):573-88
pubmed: 21669024
Nat Commun. 2020 Jan 14;11(1):246
pubmed: 31937764
Mol Psychiatry. 2019 Apr;24(4):549-561
pubmed: 29511299
Lancet. 1996 Sep 7;348(9028):692-3
pubmed: 8782788